<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01001832</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-250</org_study_id>
    <nct_id>NCT01001832</nct_id>
  </id_info>
  <brief_title>Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese Patients</brief_title>
  <official_title>A Phase II/III, Multicenter, Randomized, Double-Blind, Double-Dummy Study to Assess Similarity of the Efficacy, Pharmacokinetics, Safety and Immunogenicity of Abatacept Administered Subcutaneously or Intravenously in Japanese Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, pharmacokinetics, safety, and
      immunogenicity of abatacept after subcutaneous and intravenous administration in Japanese
      participants with active rheumatoid arthritis and inadequate response to methotrexate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Day 169 in Short Term Period</measure>
    <time_frame>Day 169</time_frame>
    <description>The ACR score of 20 indicates the degree of improvement in a patient's rheumatoid arthritis (RA), based on ACR guidelines (ACR20). The ACR score represents a percentage. To qualify for an ACR20 score, the patient must have &gt;=20% fewer tender joints and &gt;=20% fewer swollen joints and show 20% improvement in at least 3 of: patient overall assessment of his/her RA, physician global assessment of the patient's RA, patient self-assessment of pain, patient self-assessment of physical functioning, and results of an erythrocyte sedimentation rate or C-reactive protein test (to assess inflammation). Percentage is calculated n/N with n=number of participants with ACR score of 20 and N= all randomized participants who received at least one dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Sustained American College of Rheumatology (ACR) Response at Day 533 in Long Term Period - All Randomized and Treated Participants During the Long Term Period</measure>
    <time_frame>Day 533</time_frame>
    <description>The ACR score indicates the degree of improvement in a patient's rheumatoid arthritis (RA), based on ACR guidelines. The ACR score= a percentage. To qualify for a score of 20, 50 or 70 (ACR20, ACR50 or ACR70), the patient must have &gt;=20%, &gt;=50% or &gt;=70%, respectively, fewer tender joints and &gt;=20%, &gt;=50% or &gt;=70%, respectively, fewer swollen joints and show 20%, 50% or 70%, respectively, improvement in at least 3 of the following: patient overall assessment of his/her RA, physician global assessment of the patient's RA, patient self-assessment of pain, patient self-assessment of physical functioning, and results of an erythrocyte sedimentation rate or C-reactive protein test (to assess inflammation). Treatment groups represent treatment received in the short term period. Percentage calculated as n/m with n=number of paticipants with sustained ACR response at Day 533; m= long term participants who received at least one dose of drug and were ACR responders in the short term period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in HAQ-DI Score at Day 533 in Long Term Period</measure>
    <time_frame>Baseline to Day 533</time_frame>
    <description>Adjusted mean. The Health Assessment Questionnaire Disability Index (HAQ-DI) assesses patients' functional ability by rating their abilities over the previous week. At least 2 questions are asked from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. Treatment groups represent treatment received in the short term period. Baseline is Day 1 of the study or last non-missing pre-treatment value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Health Assessment Questionnaire (HAQ) Response at Day 533 in Long Term Period</measure>
    <time_frame>Day 533</time_frame>
    <description>The Health Assessment Questionnaire (HAQ) disability index assesses patients' functional ability by rating their abilities over the previous week. At least 2 questions are asked from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The higher the number the worse the outcome. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. HAQ response=reduction of at least 0.30 units in HAQ score from baseline. The percentage of participants with a reduction of at least 0.30 units in their HAQ score from baseline is presented. Baseline is Day 1 of the study or last non-missing pre-treatment value. Treatment groups represent treatment received in the short term period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change in DAS28-CRP From Baseline at Day 533 in Long Term Period</measure>
    <time_frame>Baseline to Day 533</time_frame>
    <description>The Disease Activity Score 28 using C-Reactive Protein (DAS28-CRP) is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). An overall DAS &gt;5.1 implies active disease; &lt;3.2, well controlled disease; and &lt;2.6, remission.). Treatment groups represent treatment received in the short term period. Baseline is Day 1 of the study or last non-missing pre-treatment value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With American College of Rheumatology 50 (ACR50) and American College of Rheumatology 70 (ACR70) Responses at Day 169 in Short Term Period</measure>
    <time_frame>Day 169</time_frame>
    <description>The American College of Rheumatology (ACR) scores of 50 and 70 indicates the degree of improvement in a patient's rheumatoid arthritis (RA), based on ACR guidelines. The ACR score represents a percentage. To qualify for an ACR50 or ACR70 scores, the patient must have &gt;=50% or &gt;=70%, respectively, fewer tender joints and &gt;=50% or &gt;=70%, respectively, fewer swollen joints and show 50% or 70%, respectively, improvement in at least 3 of the following: patient overall assessment of his/her RA, physician global assessment of the patient's RA, patient self-assessment of pain, patient self-assessment of physical functioning, and results of an erythrocyte sedimentation rate or C-reactive protein test (to assess inflammation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in HAQ-DI Score at Day 169 in Short Term Period</measure>
    <time_frame>Baseline to Day 169</time_frame>
    <description>Adjusted mean. The Health Assessment Questionnaire Disability Index (HAQ-DI) assesses patients' functional ability by rating their abilities over the previous week. At least 2 questions are asked from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With HAQ Response at Day 169 in the Short Term Period</measure>
    <time_frame>Day 169</time_frame>
    <description>The Health Assessment Questionnaire Disability Index (HAQ-DI) assesses patients' functional ability by rating their abilities over the previous week. At least 2 questions are asked from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. The HAQ-DI response is defined as a reduction of at least 0.30 units in HAQ score from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline at Six Months in DAS28-CRP - All Treated Participants</measure>
    <time_frame>Baseline to 6 Months</time_frame>
    <description>The Disease Activity Score 28 using C-Reactive Protein (DAS28-CRP) is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient's global assessment of health (ranging from very good to very bad). An overall DAS &gt;5.1 implies active disease; &lt;3.2, well controlled disease; and &lt;2.6, remission.). Baseline is Day 1 or last non-missing pre-treatment value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With European League Against Rheumatism (EULAR)-Defined Low Disease Activity Score (LDAS) and EULAR-defined Remission (REM) at Day 169 in Short Term Period</measure>
    <time_frame>Day 169</time_frame>
    <description>EULAR defines LDAS as DAS28-CRP less than, equal to (≤) 3.2 and defines REM as DAS28-CRP less than (&lt;) 2.6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With European League Against Rheumatism (EULAR)-Defined Low Disease Activity Score (LDAS) and EULAR-defined Remission (REM) at Day 533 in Long Term Period</measure>
    <time_frame>Day 533</time_frame>
    <description>EULAR defines LDAS as DAS28-CRP≤3.2 and defines REM as DAS28-CRP&lt;2.6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term Period: Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, Discontinuations Due to SAEs, Adverse Events (AEs), Treatment-related AEs, and Discontinuations Due to AEs</measure>
    <time_frame>Baseline to Day 169</time_frame>
    <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=related or missing relationship to study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, Discontinuations Due to SAEs, Adverse Events (AEs), Treatment-related AEs, and Discontinuations Due to AEs</measure>
    <time_frame>Baseline to Day 533 and up to 56 days following last dose in Long-Term period</time_frame>
    <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=related or missing relationship to study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term Period: Number of Participants With Hematology Laboratory Values Meeting the Criteria for Marked Abnormality</measure>
    <time_frame>Baseline to Day 169</time_frame>
    <description>lower limit of normal(LLN); upper limit of normal(ULN); pretreatment(preRX). Hemoglobin (g/dL): &gt;3 g/dL decrease from preRX; hematocrit (%): &lt;0.75*preRX; erythrocytes (*10^6 c/uL): &lt;0.75*preRX; platelet count (*10^9 c/uL): &lt;0.67*LLN or &gt;1.5*ULN, of if preRX&lt;LLN, use 0.5*preRX and &lt;100,000/mm^3; leukocytes (*10^3 c/uL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX &lt;LLN, use &lt;0.8*preRX or &gt;ULN, or if preRX&gt;ULN, use &gt;1.2*preRX or &lt;LLN; neutrophils+bands (*10^3 c/uL): if value &lt;1.0*10^3 c/uL; eosinophils (*10^3 c/uL): if value &gt;0.750*10^3 c/uL; basophils (*10^3 c/uL): if value &gt;400/mm^3; monocytes (*10^3 c/uL): if value &gt;2000/mm^3; lymphocytes (*10^3 c/uL): if value &lt;0.750*10^3 c/uL or if value &gt;7.50*10^3 c/uL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Number of Participants With Hematology Laboratory Values Meeting the Marked Abnormality Criteria</measure>
    <time_frame>Baseline to Day 533</time_frame>
    <description>LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Hemoglobin (g/dL): &gt;3 g/dL decrease from preRX; hematocrit (%): &lt;0.75*preRX; erythrocytes (*10^6 c/uL): &lt;0.75*preRX; platelet count (*10^9 c/uL): &lt;0.67*LLN or &gt;1.5*ULN, of if preRX&lt;LLN, use 0.5*preRX and &lt;100,000/mm^3; leukocytes (*10^3 c/uL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX &lt;LLN, use &lt;0.8*preRX or &gt;ULN, or if preRX&gt;ULN, use &gt;1.2*preRX or &lt;LLN; neutrophils+bands (*10^3 c/uL): if value &lt;1.0*10^3 c/uL; eosinophils (*10^3 c/uL): if value &gt;0.750*10^3 c/uL; basophils (*10^3 c/uL): if value &gt;400/mm^3; monocytes (*10^3 c/uL): if value &gt;2000/mm^3; lymphocytes (*10^3 c/uL): if value &lt;0.750*10^3 c/uL or if value &gt;7.50*10^3 c/uL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term Period: Number of Participants With Liver and Kidney Function Laboratory Values Meeting the Criteria for Marked Abnormality</measure>
    <time_frame>Baseline to Day 169</time_frame>
    <description>ULN=upper limit of normal; LLN=lower limit of normal; preRX=pretreatment. alkaline phosphatase (ALP) (U/L): &gt;2*ULN, or if preRX&gt;ULN, use &gt;3*preRX; aspartate aminotransferase (AST) (U/L): &gt;3*ULN, or if preRX&gt;ULN, use &gt;4*preRX; alanine aminotransferase(ALT) (U/L): &gt;3*ULN, or if preRX&gt;ULN, use &gt;4*preRX; Gamma glutamyltransferase(GGT) (U/L): &gt;2*ULN, or if preRX&gt;ULN, use &gt;3*preRX; bilirubin (mg/dL): &gt;2*ULN, or if preRX&gt;ULN, use &gt;4*preRX; blood urea nitrogen (mg/dL): &gt;2*preRX; creatinine (mg/dL): &gt;1.5*preRX.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-term Period: Number of Participants With Electrolyte Laboratory Values Meeting the Criteria for Marked Abnormality</measure>
    <time_frame>Baseline to Day 169</time_frame>
    <description>LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Sodium (mEq/L): &lt;0.95*LLN or &gt;1.05*ULN, or if preRX&lt;LLN, use &lt;0.95*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.05*preRX or &lt;LLN; potassium (mEq/L): &lt;0.9*LLN or &gt;1.1*ULN, or if preRX&lt;LLN, use &lt;0.9*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.1*preRX or &lt;LLN; chloride (mEq/L): &lt;0.75*LLN or &gt;1.125*ULN, or if preRX&lt;LLN, use &lt;0.75*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.25*preRX or &lt;LLN; calcium (mg/dL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX&lt;LLN, use &lt;0.75*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.25*preRX or &lt;LLN; phosphorus (mg/dL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX&lt;LLN, use &lt;0.67*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.33*preRX or &lt;LLN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Number of Participants With Liver and Kidney Function Laboratory Values Meeting the Criteria for Marked Abnormality</measure>
    <time_frame>Baseline to Day 533</time_frame>
    <description>ULN=upper limit of normal; LLN=lower limit of normal; preRX=pretreatment. ALP (U/L): &gt;2*ULN, or if preRX&gt;ULN, use &gt;3*preRX; AST (U/L): &gt;3*ULN, or if preRX&gt;ULN, use &gt;4*preRX; ALT (U/L): &gt;3*ULN, or if preRX&gt;ULN, use &gt;4*preRX; GGT (U/L): &gt;2*ULN, or if preRX&gt;ULN, use &gt;3*preRX; bilirubin (mg/dL): &gt;2*ULN, or if preRX&gt;ULN, use &gt;4*preRX; blood urea nitrogen (mg/dL): &gt;2*preRX; creatinine (mg/dL): &gt;1.5*preRX.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Period: Number of Participants With Electrolyte Laboratory Values Meeting the Criteria for Marked Abnormality</measure>
    <time_frame>Baseline to Day 533</time_frame>
    <description>LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Sodium (mEq/L): &lt;0.95*LLN or &gt;1.05*ULN, or if preRX&lt;LLN, use &lt;0.95*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.05*preRX or &lt;LLN; potassium (mEq/L): &lt;0.9*LLN or &gt;1.1*ULN, or if preRX&lt;LLN, use &lt;0.9*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.1*preRX or &lt;LLN; chloride (mEq/L): &lt;0.75*LLN or &gt;1.125*ULN, or if preRX&lt;LLN, use &lt;0.75*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.25*preRX or &lt;LLN; calcium (mg/dL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX&lt;LLN, use &lt;0.75*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.25*preRX or &lt;LLN; phosphorus (mg/dL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX&lt;LLN, use &lt;0.67*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.33*preRX or &lt;LLN.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Subcutaneous (SC) abatacept, 125 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous (IV) abatacept, 125 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous (IV) abatacept</intervention_name>
    <description>IV vial, 125-mg infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141.</description>
    <arm_group_label>Intravenous (IV) abatacept, 125 mg</arm_group_label>
    <other_name>BMS-188667</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous (SC) abatacept</intervention_name>
    <description>Solution in prefilled syringes, SC, 125 mg, once weekly, for 169 days and then for 52 weeks</description>
    <arm_group_label>Subcutaneous (SC) abatacept, 125 mg</arm_group_label>
    <other_name>BMS-188667</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Meeting criteria of the American Rheumatism Association for the diagnosis of
             rheumatoid arthritis (RA) and the American College of Rheumatology functional Classes
             I, II, or III.

          -  Inadequate response (as deemed by investigator) to methotrexate taken for at least 3
             months (12 weeks) at a stable dose (6 to 8 mg/week) for 28 days prior to randomization
             (Day 1).

          -  Stabilization requirements for concomitant therapy: Oral corticosteroid treatment
             reduced to the equivalent of ≤10 mg prednisolone daily for 28 days and stabilized for
             at least 25 of 28 days prior to treatment (Day 1). No intra-articular, intravenous, or
             intramuscular injections of corticosteroids were permitted within 28 days prior to
             randomization (Day 1.)

          -  Washout requirements: Participants receiving combination RA therapy had to discontinue
             the following therapies at least 28 days prior to treatment (Day 1):

        disease-modifying antirheumatic drugs (DMARDs), such as gold (auranofin and aurothiomalate
        sodium), actarit, bucillamine, azathioprine, salazosulfapyridine, lobenzarit disodium,
        D-penicillamine, cyclophosphamide, mycophenolate mofetil, mizoribine; cyclosporin,
        tacrolimus, and other calcineurin inhibitors; and immunoadsorption columns.

          -  Disease Activity Requirements: At randomization (Day 1), participants had to meet the
             following disease activity criteria: Swollen joint count: 10 or more swollen joints
             (66 joint count); tender joint count: 12 or more tender joints (68 joint count); C
             reactive protein (CRP): ≥0.8 mg/dL (result from screening visit).

          -  For participants receiving methotrexate plus other DMARDs(washout of a combination
             therapy required): At screening visit, participants had to meet the following disease
             activity criteria: Swollen joint count: 6 or more swollen joints (66 joint count);
             tender joint count: 8 or more tender joints (68 joint count); CRP: no restriction on
             CRP (not applicable).

          -  After washout, at randomization (Day 1), participants must meet the following disease
             activity criteria: Swollen joint count-10 or more swollen joints (66 joint count) and
             tender joint count-12 or more tender joints (68 joint count) and CRP: ≥0.8 mg/dL
             (result from screening visit). For those whose screening period were longer than 4
             weeks, CRP test needed to be performed on Day −28 to Day −3 (prior to treatment Day 1)
             to verify eligibility.

        Key Exclusion Criteria:

          -  Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematologic,
             gastrointestinal, pulmonary, cardiac, neurologic, or cerebral disease. Concomitant
             medical conditions that, in the opinion of the investigator, might place the
             participant at unacceptable risk for participation in this study.

          -  Female participants who had undergone breast cancer screening that was suspicious for
             malignancy, and in whom the possibility of malignancy could not be reasonably excluded
             following additional clinical, laboratory, or other diagnostic evaluations.

          -  History of cancer within the last 5 years (other than nonmelanoma skin cell cancers
             cured by local resection)

          -  Existing nonmelanoma skin cell cancers had been removed prior to the first
             administration. Participants with carcinoma in situ, treated with definitive surgical
             intervention prior to study entry were allowed to participate.

          -  Clinically significant drug or alcohol abuse

          -  Any serious acute bacterial infection (such as pneumonia or pyelonephritis unless
             treated and completely resolved with antibiotics)

          -  Serious, chronic, or recurrent bacterial infections (such as recurrent pneumonia,
             chronic bronchiectasis)

          -  Those at risk for tuberculosis (TB). Specifically, those with current clinical,
             radiographic, or laboratory evidence suggestive of active TB; history of active TB
             within the last 3 years, even if treated; history of active TB more than 3 years ago
             unless there was documentation that the prior anti-TB treatment was appropriate in
             type and duration; latent TB that was not successfully treated. Participants with a
             positive result on TB screening test indicative of latent TB were not eligible for the
             study unless active TB infection had been ruled out and treatment for latent TB with
             isoniazid had been initiated for at least 4 weeks prior to administration of the study
             drug and the participant had a negative finding for TB on a chest X-ray film at
             enrollment.

          -  Herpes zoster resolving less than 2 months prior to enrollment

          -  Current evidence (as assessed by the investigator) suggestive of active or latent
             bacterial or viral infections, including human immunodeficiency virus infection.

          -  Physical examination and laboratory test findings: Hepatitis B surface
             antigen-positive status; hepatitis C antibody-positive status. Any of the following
             laboratory values: Hemoglobin concentration: &lt;.5 g/dL; white blood cell count:
             &lt;3,000/μL (3*10^9/L); platelet count: &lt;100,000/mm^3(100*10^9/L); serum creatinine: &gt;2
             times upper limit of normal (ULN); serum alanine aminotransferase: &gt;2 ULN; serum
             aspartate aminotransferase: &gt;2 ULN.

          -  Prohibited treatments and/or therapies: Prior exposure to abatacept (CTLA4-Ig); prior
             RA treatment with any biologics, such as anti-tumor necrosis factor therapy; prior
             exposure to any investigational biologic not currently approved in Japan; exposure to
             any study medication in any other previous study within 4 weeks or 5 half-lives,
             whichever was longer; receipt of any live vaccines within 3 months of administration
             of study medication or scheduled to receive live vaccines.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Narita-Shi</city>
        <state>Chiba</state>
        <zip>2868523</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fukuoka-Shi</city>
        <state>Fukuoka</state>
        <zip>8108563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kitakyushu-Shi</city>
        <state>Fukuoka</state>
        <zip>8078555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kurume-Shi</city>
        <state>Fukuoka</state>
        <zip>8308543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Maebashi-Shi</city>
        <state>Gunma</state>
        <zip>3718511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Takasaki-Shi</city>
        <state>Gunma</state>
        <zip>3700053</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Higashi-Hiroshima-Shi</city>
        <state>Hiroshima</state>
        <zip>7390002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sapporo-Shi</city>
        <state>Hokkaido</state>
        <zip>0608604</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sapporo-Shi</city>
        <state>Hokkaido</state>
        <zip>0608648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sapporo-Shi</city>
        <state>Hokkaido</state>
        <zip>0630811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>0630005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kanzaki-Gun</city>
        <state>Hyogo</state>
        <zip>6792414</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kato-Shi</city>
        <state>Hyogo</state>
        <zip>6731462</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kobe-Shi</city>
        <state>Hyogo</state>
        <zip>6500001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hitachi-Shi</city>
        <state>Ibaraki</state>
        <zip>3160035</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kagoshima-Shi</city>
        <state>Kagoshima</state>
        <zip>8900067</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sagamihara-Shi</city>
        <state>Kanagawa</state>
        <zip>2520392</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Yokohama-Shi</city>
        <state>Kanagawa</state>
        <zip>2220036</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Yokohama-Shi</city>
        <state>Kanagawa</state>
        <zip>2360037</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nagano-Shi</city>
        <state>Nagano</state>
        <zip>3808582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kurashiki-Shi</city>
        <state>Okayama</state>
        <zip>7128044</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hannan-Shi</city>
        <state>Osaka</state>
        <zip>5990212</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Iruma-Gun</city>
        <state>Saitama</state>
        <zip>3500495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kawagoe-Shi</city>
        <state>Saitama</state>
        <zip>3508550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kitamoto-Shi</city>
        <state>Saitama</state>
        <zip>3640026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tokorozawa-Shi</city>
        <state>Saitama</state>
        <zip>3591111</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamamatsu-Shi</city>
        <state>Shizuoka</state>
        <zip>4308558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shizuoka-Shi</city>
        <state>Shizuoka</state>
        <zip>4208623</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shimotsuke-Shi</city>
        <state>Tochigi</state>
        <zip>3290498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Utsunomiya-Shi</city>
        <state>Tochigi</state>
        <zip>3291193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bunkyo-Ku</city>
        <state>Tokyo</state>
        <zip>1138519</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nakano-Ku</city>
        <state>Tokyo</state>
        <zip>1648541</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shinjuku-Ku</city>
        <state>Tokyo</state>
        <zip>1608582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2009</study_first_submitted>
  <study_first_submitted_qc>October 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2009</study_first_posted>
  <results_first_submitted>October 22, 2012</results_first_submitted>
  <results_first_submitted_qc>January 8, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 7, 2013</results_first_posted>
  <last_update_submitted>January 2, 2014</last_update_submitted>
  <last_update_submitted_qc>January 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study started 8 December 2009; short-term period ended 25 February 2011; long-term period ended 26 October 2012.</recruitment_details>
      <pre_assignment_details>171 participants were enrolled, 118 participants were randomized and treated in the short-term period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Subcutaneous (SC) Abatacept, 125 mg</title>
          <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
        </group>
        <group group_id="P2">
          <title>Intravenous (IV) Abatacept, 125 mg</title>
          <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Short-term Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long-term Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56">1 participant completed the short term period but discontinued before start of the Long-term Period.</participants>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Follow-up no longer required /protocol</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not specified</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subcutaneous (SC) Abatacept, 125 mg</title>
          <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
        </group>
        <group group_id="B2">
          <title>Intravenous (IV) Abatacept, 125 mg</title>
          <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="118"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.1" spread="12.3"/>
                    <measurement group_id="B2" value="55.2" spread="13.6"/>
                    <measurement group_id="B3" value="55.6" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian (not Japanese)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Disease</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.5" spread="9.2"/>
                    <measurement group_id="B2" value="5.3" spread="7.3"/>
                    <measurement group_id="B3" value="6.4" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Disease Category</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;= 2 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" spread="42.4"/>
                    <measurement group_id="B2" value="30" spread="50.8"/>
                    <measurement group_id="B3" value="55" spread="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;2 to &lt;= 5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" spread="11.9"/>
                    <measurement group_id="B2" value="11" spread="18.6"/>
                    <measurement group_id="B3" value="18" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;5 to &lt;= 10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" spread="16.9"/>
                    <measurement group_id="B2" value="6" spread="10.2"/>
                    <measurement group_id="B3" value="16" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;10 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17" spread="28.8"/>
                    <measurement group_id="B2" value="12" spread="20.3"/>
                    <measurement group_id="B3" value="29" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tender Joint Count</title>
          <description>The number of joints the participant finds painful (tender) is counted by the investigator.</description>
          <units>Number of joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.9" spread="9.3"/>
                    <measurement group_id="B2" value="22.3" spread="9.9"/>
                    <measurement group_id="B3" value="21.6" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swollen Joint Count</title>
          <description>the number of the participants' joints that the investigator observes is swollen.</description>
          <units>Number of joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.4" spread="7.0"/>
                    <measurement group_id="B2" value="17.6" spread="7.2"/>
                    <measurement group_id="B3" value="17.0" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DAS28-CRP</title>
          <description>The Disease Activity Score 28 using C-Reactive Protein (DAS28-CRP) is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient’s global assessment of health (ranging from very good to very bad). These measures are then fed into a complex mathematical formula to produce the overall DAS (greater than 5.1 implies active disease; less than 3.2, well controlled disease; and less than 2.6, remission.)</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.62" spread="0.84"/>
                    <measurement group_id="B2" value="5.95" spread="0.91"/>
                    <measurement group_id="B3" value="5.79" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HAQ Score</title>
          <description>The Health Assessment Questionnaire(HAQ) Disability Index (DI) assesses patients' functional ability by rating their abilities over the previous week. At least 2 questions are asked from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.28" spread="0.690"/>
                    <measurement group_id="B2" value="1.32" spread="0.64"/>
                    <measurement group_id="B3" value="1.30" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Methotrexate dose</title>
          <description>The methotrexate dose is the calculated weekly total dose in the week ending at the first dose date of the Short-term Period.</description>
          <units>mg/week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3" spread="1.0"/>
                    <measurement group_id="B2" value="7.3" spread="1.0"/>
                    <measurement group_id="B3" value="7.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Day 169 in Short Term Period</title>
        <description>The ACR score of 20 indicates the degree of improvement in a patient's rheumatoid arthritis (RA), based on ACR guidelines (ACR20). The ACR score represents a percentage. To qualify for an ACR20 score, the patient must have &gt;=20% fewer tender joints and &gt;=20% fewer swollen joints and show 20% improvement in at least 3 of: patient overall assessment of his/her RA, physician global assessment of the patient’s RA, patient self-assessment of pain, patient self-assessment of physical functioning, and results of an erythrocyte sedimentation rate or C-reactive protein test (to assess inflammation). Percentage is calculated n/N with n=number of participants with ACR score of 20 and N= all randomized participants who received at least one dose of study drug.</description>
        <time_frame>Day 169</time_frame>
        <population>N= All randomized participants who received at least 1 dose of study medication and were analyzed. n=number of participants with ACR20 response at Day 169: 54, 49, respectively. n/N= percentage: 54/59; 49/59.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Day 169 in Short Term Period</title>
          <description>The ACR score of 20 indicates the degree of improvement in a patient's rheumatoid arthritis (RA), based on ACR guidelines (ACR20). The ACR score represents a percentage. To qualify for an ACR20 score, the patient must have &gt;=20% fewer tender joints and &gt;=20% fewer swollen joints and show 20% improvement in at least 3 of: patient overall assessment of his/her RA, physician global assessment of the patient’s RA, patient self-assessment of pain, patient self-assessment of physical functioning, and results of an erythrocyte sedimentation rate or C-reactive protein test (to assess inflammation). Percentage is calculated n/N with n=number of participants with ACR score of 20 and N= all randomized participants who received at least one dose of study drug.</description>
          <population>N= All randomized participants who received at least 1 dose of study medication and were analyzed. n=number of participants with ACR20 response at Day 169: 54, 49, respectively. n/N= percentage: 54/59; 49/59.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.5" lower_limit="81.3" upper_limit="97.2"/>
                    <measurement group_id="O2" value="83.1" lower_limit="71.0" upper_limit="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With American College of Rheumatology 50 (ACR50) and American College of Rheumatology 70 (ACR70) Responses at Day 169 in Short Term Period</title>
        <description>The American College of Rheumatology (ACR) scores of 50 and 70 indicates the degree of improvement in a patient's rheumatoid arthritis (RA), based on ACR guidelines. The ACR score represents a percentage. To qualify for an ACR50 or ACR70 scores, the patient must have &gt;=50% or &gt;=70%, respectively, fewer tender joints and &gt;=50% or &gt;=70%, respectively, fewer swollen joints and show 50% or 70%, respectively, improvement in at least 3 of the following: patient overall assessment of his/her RA, physician global assessment of the patient’s RA, patient self-assessment of pain, patient self-assessment of physical functioning, and results of an erythrocyte sedimentation rate or C-reactive protein test (to assess inflammation).</description>
        <time_frame>Day 169</time_frame>
        <population>m= All participants who received at least 1 dose of study medication in short term period and had data available. n= participants with ACR50 or ACR70 response in the short term period. n/m= percentage</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With American College of Rheumatology 50 (ACR50) and American College of Rheumatology 70 (ACR70) Responses at Day 169 in Short Term Period</title>
          <description>The American College of Rheumatology (ACR) scores of 50 and 70 indicates the degree of improvement in a patient's rheumatoid arthritis (RA), based on ACR guidelines. The ACR score represents a percentage. To qualify for an ACR50 or ACR70 scores, the patient must have &gt;=50% or &gt;=70%, respectively, fewer tender joints and &gt;=50% or &gt;=70%, respectively, fewer swollen joints and show 50% or 70%, respectively, improvement in at least 3 of the following: patient overall assessment of his/her RA, physician global assessment of the patient’s RA, patient self-assessment of pain, patient self-assessment of physical functioning, and results of an erythrocyte sedimentation rate or C-reactive protein test (to assess inflammation).</description>
          <population>m= All participants who received at least 1 dose of study medication in short term period and had data available. n= participants with ACR50 or ACR70 response in the short term period. n/m= percentage</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR50 (n/m=39/59, 37/59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.1" lower_limit="52.6" upper_limit="77.9"/>
                    <measurement group_id="O2" value="62.7" lower_limit="49.1" upper_limit="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 (n/m=22/59, 18/59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3" lower_limit="25.0" upper_limit="50.9"/>
                    <measurement group_id="O2" value="30.5" lower_limit="19.2" upper_limit="43.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in HAQ-DI Score at Day 169 in Short Term Period</title>
        <description>Adjusted mean. The Health Assessment Questionnaire Disability Index (HAQ-DI) assesses patients' functional ability by rating their abilities over the previous week. At least 2 questions are asked from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3.</description>
        <time_frame>Baseline to Day 169</time_frame>
        <population>All participants who received at least 1 dose of study medication were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HAQ-DI Score at Day 169 in Short Term Period</title>
          <description>Adjusted mean. The Health Assessment Questionnaire Disability Index (HAQ-DI) assesses patients' functional ability by rating their abilities over the previous week. At least 2 questions are asked from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3.</description>
          <population>All participants who received at least 1 dose of study medication were analyzed.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.62" lower_limit="-0.74" upper_limit="-0.49"/>
                    <measurement group_id="O2" value="-0.61" lower_limit="-0.73" upper_limit="-0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With HAQ Response at Day 169 in the Short Term Period</title>
        <description>The Health Assessment Questionnaire Disability Index (HAQ-DI) assesses patients' functional ability by rating their abilities over the previous week. At least 2 questions are asked from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. The HAQ-DI response is defined as a reduction of at least 0.30 units in HAQ score from baseline.</description>
        <time_frame>Day 169</time_frame>
        <population>N=All randomized participants who received at least 1 dose of study medication in short term period. n=number of participants with HAQ response in short term period; n/N=percentage of participants: 41/59 and 30/59</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With HAQ Response at Day 169 in the Short Term Period</title>
          <description>The Health Assessment Questionnaire Disability Index (HAQ-DI) assesses patients' functional ability by rating their abilities over the previous week. At least 2 questions are asked from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. The HAQ-DI response is defined as a reduction of at least 0.30 units in HAQ score from baseline.</description>
          <population>N=All randomized participants who received at least 1 dose of study medication in short term period. n=number of participants with HAQ response in short term period; n/N=percentage of participants: 41/59 and 30/59</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.5" lower_limit="56.1" upper_limit="80.8"/>
                    <measurement group_id="O2" value="50.8" lower_limit="37.5" upper_limit="64.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline at Six Months in DAS28-CRP - All Treated Participants</title>
        <description>The Disease Activity Score 28 using C-Reactive Protein (DAS28-CRP) is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient’s global assessment of health (ranging from very good to very bad). An overall DAS &gt;5.1 implies active disease; &lt;3.2, well controlled disease; and &lt;2.6, remission.). Baseline is Day 1 or last non-missing pre-treatment value.</description>
        <time_frame>Baseline to 6 Months</time_frame>
        <population>All participants who received at least 1 dose of study medication with both baseline and post-baseline measurements were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline at Six Months in DAS28-CRP - All Treated Participants</title>
          <description>The Disease Activity Score 28 using C-Reactive Protein (DAS28-CRP) is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient’s global assessment of health (ranging from very good to very bad). An overall DAS &gt;5.1 implies active disease; &lt;3.2, well controlled disease; and &lt;2.6, remission.). Baseline is Day 1 or last non-missing pre-treatment value.</description>
          <population>All participants who received at least 1 dose of study medication with both baseline and post-baseline measurements were analyzed.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.97" lower_limit="-3.25" upper_limit="-2.70"/>
                    <measurement group_id="O2" value="-2.75" lower_limit="-3.03" upper_limit="-2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With European League Against Rheumatism (EULAR)-Defined Low Disease Activity Score (LDAS) and EULAR-defined Remission (REM) at Day 169 in Short Term Period</title>
        <description>EULAR defines LDAS as DAS28-CRP less than, equal to (≤) 3.2 and defines REM as DAS28-CRP less than (&lt;) 2.6.</description>
        <time_frame>Day 169</time_frame>
        <population>m=All randomized participants who received at least 1 dose of study medication and with LDAS and REM data available. n= number of participants with LDAS and REM. n/m=percentage of participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With European League Against Rheumatism (EULAR)-Defined Low Disease Activity Score (LDAS) and EULAR-defined Remission (REM) at Day 169 in Short Term Period</title>
          <description>EULAR defines LDAS as DAS28-CRP less than, equal to (≤) 3.2 and defines REM as DAS28-CRP less than (&lt;) 2.6.</description>
          <population>m=All randomized participants who received at least 1 dose of study medication and with LDAS and REM data available. n= number of participants with LDAS and REM. n/m=percentage of participants.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDAS (n/m= 40/57, 38/57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.2" lower_limit="56.6" upper_limit="81.6"/>
                    <measurement group_id="O2" value="66.7" lower_limit="52.9" upper_limit="78.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM (n/m= 29/57, 23/57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.9" lower_limit="37.3" upper_limit="64.4"/>
                    <measurement group_id="O2" value="40.4" lower_limit="27.6" upper_limit="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With European League Against Rheumatism (EULAR)-Defined Low Disease Activity Score (LDAS) and EULAR-defined Remission (REM) at Day 533 in Long Term Period</title>
        <description>EULAR defines LDAS as DAS28-CRP≤3.2 and defines REM as DAS28-CRP&lt;2.6.</description>
        <time_frame>Day 533</time_frame>
        <population>m=All treated participants in the long term period in the analysis with available LDAS and REM data. n=number of participants with either EULAR-defined LDAS response or EULAR-defined REM response. n/m = percentage of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With European League Against Rheumatism (EULAR)-Defined Low Disease Activity Score (LDAS) and EULAR-defined Remission (REM) at Day 533 in Long Term Period</title>
          <description>EULAR defines LDAS as DAS28-CRP≤3.2 and defines REM as DAS28-CRP&lt;2.6.</description>
          <population>m=All treated participants in the long term period in the analysis with available LDAS and REM data. n=number of participants with either EULAR-defined LDAS response or EULAR-defined REM response. n/m = percentage of participants</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LDAS (n/m= 45/52, 42/51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5" lower_limit="74.2" upper_limit="94.4"/>
                    <measurement group_id="O2" value="82.4" lower_limit="69.1" upper_limit="91.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM (n/m= 33/52; 32/51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5" lower_limit="49.0" upper_limit="76.4"/>
                    <measurement group_id="O2" value="62.7" lower_limit="48.1" upper_limit="75.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-term Period: Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, Discontinuations Due to SAEs, Adverse Events (AEs), Treatment-related AEs, and Discontinuations Due to AEs</title>
        <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=related or missing relationship to study medication.</description>
        <time_frame>Baseline to Day 169</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, Discontinuations Due to SAEs, Adverse Events (AEs), Treatment-related AEs, and Discontinuations Due to AEs</title>
          <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=related or missing relationship to study medication.</description>
          <population>All randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations due to SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, Discontinuations Due to SAEs, Adverse Events (AEs), Treatment-related AEs, and Discontinuations Due to AEs</title>
        <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=related or missing relationship to study medication.</description>
        <time_frame>Baseline to Day 533 and up to 56 days following last dose in Long-Term period</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, Discontinuations Due to SAEs, Adverse Events (AEs), Treatment-related AEs, and Discontinuations Due to AEs</title>
          <description>AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=related or missing relationship to study medication.</description>
          <population>All randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation due to SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuation due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-term Period: Number of Participants With Hematology Laboratory Values Meeting the Criteria for Marked Abnormality</title>
        <description>lower limit of normal(LLN); upper limit of normal(ULN); pretreatment(preRX). Hemoglobin (g/dL): &gt;3 g/dL decrease from preRX; hematocrit (%): &lt;0.75*preRX; erythrocytes (*10^6 c/uL): &lt;0.75*preRX; platelet count (*10^9 c/uL): &lt;0.67*LLN or &gt;1.5*ULN, of if preRX&lt;LLN, use 0.5*preRX and &lt;100,000/mm^3; leukocytes (*10^3 c/uL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX &lt;LLN, use &lt;0.8*preRX or &gt;ULN, or if preRX&gt;ULN, use &gt;1.2*preRX or &lt;LLN; neutrophils+bands (*10^3 c/uL): if value &lt;1.0*10^3 c/uL; eosinophils (*10^3 c/uL): if value &gt;0.750*10^3 c/uL; basophils (*10^3 c/uL): if value &gt;400/mm^3; monocytes (*10^3 c/uL): if value &gt;2000/mm^3; lymphocytes (*10^3 c/uL): if value &lt;0.750*10^3 c/uL or if value &gt;7.50*10^3 c/uL.</description>
        <time_frame>Baseline to Day 169</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Number of Participants With Hematology Laboratory Values Meeting the Criteria for Marked Abnormality</title>
          <description>lower limit of normal(LLN); upper limit of normal(ULN); pretreatment(preRX). Hemoglobin (g/dL): &gt;3 g/dL decrease from preRX; hematocrit (%): &lt;0.75*preRX; erythrocytes (*10^6 c/uL): &lt;0.75*preRX; platelet count (*10^9 c/uL): &lt;0.67*LLN or &gt;1.5*ULN, of if preRX&lt;LLN, use 0.5*preRX and &lt;100,000/mm^3; leukocytes (*10^3 c/uL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX &lt;LLN, use &lt;0.8*preRX or &gt;ULN, or if preRX&gt;ULN, use &gt;1.2*preRX or &lt;LLN; neutrophils+bands (*10^3 c/uL): if value &lt;1.0*10^3 c/uL; eosinophils (*10^3 c/uL): if value &gt;0.750*10^3 c/uL; basophils (*10^3 c/uL): if value &gt;400/mm^3; monocytes (*10^3 c/uL): if value &gt;2000/mm^3; lymphocytes (*10^3 c/uL): if value &lt;0.750*10^3 c/uL or if value &gt;7.50*10^3 c/uL.</description>
          <population>All randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils + bands (absolute), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils + bands (absolute), high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (absolute), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (absolute), high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils (absolute), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils (absolute), high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes (absolute), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes (absolute), high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (absolute), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (absolute), high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Number of Participants With Hematology Laboratory Values Meeting the Marked Abnormality Criteria</title>
        <description>LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Hemoglobin (g/dL): &gt;3 g/dL decrease from preRX; hematocrit (%): &lt;0.75*preRX; erythrocytes (*10^6 c/uL): &lt;0.75*preRX; platelet count (*10^9 c/uL): &lt;0.67*LLN or &gt;1.5*ULN, of if preRX&lt;LLN, use 0.5*preRX and &lt;100,000/mm^3; leukocytes (*10^3 c/uL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX &lt;LLN, use &lt;0.8*preRX or &gt;ULN, or if preRX&gt;ULN, use &gt;1.2*preRX or &lt;LLN; neutrophils+bands (*10^3 c/uL): if value &lt;1.0*10^3 c/uL; eosinophils (*10^3 c/uL): if value &gt;0.750*10^3 c/uL; basophils (*10^3 c/uL): if value &gt;400/mm^3; monocytes (*10^3 c/uL): if value &gt;2000/mm^3; lymphocytes (*10^3 c/uL): if value &lt;0.750*10^3 c/uL or if value &gt;7.50*10^3 c/uL.</description>
        <time_frame>Baseline to Day 533</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Number of Participants With Hematology Laboratory Values Meeting the Marked Abnormality Criteria</title>
          <description>LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Hemoglobin (g/dL): &gt;3 g/dL decrease from preRX; hematocrit (%): &lt;0.75*preRX; erythrocytes (*10^6 c/uL): &lt;0.75*preRX; platelet count (*10^9 c/uL): &lt;0.67*LLN or &gt;1.5*ULN, of if preRX&lt;LLN, use 0.5*preRX and &lt;100,000/mm^3; leukocytes (*10^3 c/uL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX &lt;LLN, use &lt;0.8*preRX or &gt;ULN, or if preRX&gt;ULN, use &gt;1.2*preRX or &lt;LLN; neutrophils+bands (*10^3 c/uL): if value &lt;1.0*10^3 c/uL; eosinophils (*10^3 c/uL): if value &gt;0.750*10^3 c/uL; basophils (*10^3 c/uL): if value &gt;400/mm^3; monocytes (*10^3 c/uL): if value &gt;2000/mm^3; lymphocytes (*10^3 c/uL): if value &lt;0.750*10^3 c/uL or if value &gt;7.50*10^3 c/uL.</description>
          <population>All randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated.</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated.</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocytes, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated.</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils + bands (absolute), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils + bands (absolute), high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated.</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (absolute), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated.</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils (absolute), high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils (absolute), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated.</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils (absolute), high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes (absolute), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated.</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes (absolute), high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (absolute), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (absolute), high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-term Period: Number of Participants With Liver and Kidney Function Laboratory Values Meeting the Criteria for Marked Abnormality</title>
        <description>ULN=upper limit of normal; LLN=lower limit of normal; preRX=pretreatment. alkaline phosphatase (ALP) (U/L): &gt;2*ULN, or if preRX&gt;ULN, use &gt;3*preRX; aspartate aminotransferase (AST) (U/L): &gt;3*ULN, or if preRX&gt;ULN, use &gt;4*preRX; alanine aminotransferase(ALT) (U/L): &gt;3*ULN, or if preRX&gt;ULN, use &gt;4*preRX; Gamma glutamyltransferase(GGT) (U/L): &gt;2*ULN, or if preRX&gt;ULN, use &gt;3*preRX; bilirubin (mg/dL): &gt;2*ULN, or if preRX&gt;ULN, use &gt;4*preRX; blood urea nitrogen (mg/dL): &gt;2*preRX; creatinine (mg/dL): &gt;1.5*preRX.</description>
        <time_frame>Baseline to Day 169</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Number of Participants With Liver and Kidney Function Laboratory Values Meeting the Criteria for Marked Abnormality</title>
          <description>ULN=upper limit of normal; LLN=lower limit of normal; preRX=pretreatment. alkaline phosphatase (ALP) (U/L): &gt;2*ULN, or if preRX&gt;ULN, use &gt;3*preRX; aspartate aminotransferase (AST) (U/L): &gt;3*ULN, or if preRX&gt;ULN, use &gt;4*preRX; alanine aminotransferase(ALT) (U/L): &gt;3*ULN, or if preRX&gt;ULN, use &gt;4*preRX; Gamma glutamyltransferase(GGT) (U/L): &gt;2*ULN, or if preRX&gt;ULN, use &gt;3*preRX; bilirubin (mg/dL): &gt;2*ULN, or if preRX&gt;ULN, use &gt;4*preRX; blood urea nitrogen (mg/dL): &gt;2*preRX; creatinine (mg/dL): &gt;1.5*preRX.</description>
          <population>All randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline phosphatase (ALP), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase (AST), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine aminotransferase (ALT), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-glutamyl transferase (GGT), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, total, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, total, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Short-term Period: Number of Participants With Electrolyte Laboratory Values Meeting the Criteria for Marked Abnormality</title>
        <description>LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Sodium (mEq/L): &lt;0.95*LLN or &gt;1.05*ULN, or if preRX&lt;LLN, use &lt;0.95*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.05*preRX or &lt;LLN; potassium (mEq/L): &lt;0.9*LLN or &gt;1.1*ULN, or if preRX&lt;LLN, use &lt;0.9*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.1*preRX or &lt;LLN; chloride (mEq/L): &lt;0.75*LLN or &gt;1.125*ULN, or if preRX&lt;LLN, use &lt;0.75*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.25*preRX or &lt;LLN; calcium (mg/dL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX&lt;LLN, use &lt;0.75*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.25*preRX or &lt;LLN; phosphorus (mg/dL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX&lt;LLN, use &lt;0.67*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.33*preRX or &lt;LLN.</description>
        <time_frame>Baseline to Day 169</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Short-term Period: Number of Participants With Electrolyte Laboratory Values Meeting the Criteria for Marked Abnormality</title>
          <description>LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Sodium (mEq/L): &lt;0.95*LLN or &gt;1.05*ULN, or if preRX&lt;LLN, use &lt;0.95*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.05*preRX or &lt;LLN; potassium (mEq/L): &lt;0.9*LLN or &gt;1.1*ULN, or if preRX&lt;LLN, use &lt;0.9*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.1*preRX or &lt;LLN; chloride (mEq/L): &lt;0.75*LLN or &gt;1.125*ULN, or if preRX&lt;LLN, use &lt;0.75*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.25*preRX or &lt;LLN; calcium (mg/dL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX&lt;LLN, use &lt;0.75*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.25*preRX or &lt;LLN; phosphorus (mg/dL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX&lt;LLN, use &lt;0.67*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.33*preRX or &lt;LLN.</description>
          <population>All randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium, serum, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, serum, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, serum, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, serum, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, serum, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, serum, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, total, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, total, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus, inorganic, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus, inorganic, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Number of Participants With Liver and Kidney Function Laboratory Values Meeting the Criteria for Marked Abnormality</title>
        <description>ULN=upper limit of normal; LLN=lower limit of normal; preRX=pretreatment. ALP (U/L): &gt;2*ULN, or if preRX&gt;ULN, use &gt;3*preRX; AST (U/L): &gt;3*ULN, or if preRX&gt;ULN, use &gt;4*preRX; ALT (U/L): &gt;3*ULN, or if preRX&gt;ULN, use &gt;4*preRX; GGT (U/L): &gt;2*ULN, or if preRX&gt;ULN, use &gt;3*preRX; bilirubin (mg/dL): &gt;2*ULN, or if preRX&gt;ULN, use &gt;4*preRX; blood urea nitrogen (mg/dL): &gt;2*preRX; creatinine (mg/dL): &gt;1.5*preRX.</description>
        <time_frame>Baseline to Day 533</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Number of Participants With Liver and Kidney Function Laboratory Values Meeting the Criteria for Marked Abnormality</title>
          <description>ULN=upper limit of normal; LLN=lower limit of normal; preRX=pretreatment. ALP (U/L): &gt;2*ULN, or if preRX&gt;ULN, use &gt;3*preRX; AST (U/L): &gt;3*ULN, or if preRX&gt;ULN, use &gt;4*preRX; ALT (U/L): &gt;3*ULN, or if preRX&gt;ULN, use &gt;4*preRX; GGT (U/L): &gt;2*ULN, or if preRX&gt;ULN, use &gt;3*preRX; bilirubin (mg/dL): &gt;2*ULN, or if preRX&gt;ULN, use &gt;4*preRX; blood urea nitrogen (mg/dL): &gt;2*preRX; creatinine (mg/dL): &gt;1.5*preRX.</description>
          <population>All randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Alkaline phosphatase (ALP), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated.</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase (AST), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated.</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine aminotransferase (ALT), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated.</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-glutamyl transferase (GGT), low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated.</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, total, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated.</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, total, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated.</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood urea nitrogen, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not evaluated.</measurement>
                    <measurement group_id="O2" value="NA">Not evaluated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Sustained American College of Rheumatology (ACR) Response at Day 533 in Long Term Period - All Randomized and Treated Participants During the Long Term Period</title>
        <description>The ACR score indicates the degree of improvement in a patient's rheumatoid arthritis (RA), based on ACR guidelines. The ACR score= a percentage. To qualify for a score of 20, 50 or 70 (ACR20, ACR50 or ACR70), the patient must have &gt;=20%, &gt;=50% or &gt;=70%, respectively, fewer tender joints and &gt;=20%, &gt;=50% or &gt;=70%, respectively, fewer swollen joints and show 20%, 50% or 70%, respectively, improvement in at least 3 of the following: patient overall assessment of his/her RA, physician global assessment of the patient’s RA, patient self-assessment of pain, patient self-assessment of physical functioning, and results of an erythrocyte sedimentation rate or C-reactive protein test (to assess inflammation). Treatment groups represent treatment received in the short term period. Percentage calculated as n/m with n=number of paticipants with sustained ACR response at Day 533; m= long term participants who received at least one dose of drug and were ACR responders in the short term period.</description>
        <time_frame>Day 533</time_frame>
        <population>m=Long term period participants who received at least one dose of drug and were ACR responders in short term period: ACR20= 49, 46; ACR50= 35, 34; ACR70= 20, 16. n=number of paticipants with sustained ACR response at Day 533. n/m = percentage</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Sustained American College of Rheumatology (ACR) Response at Day 533 in Long Term Period - All Randomized and Treated Participants During the Long Term Period</title>
          <description>The ACR score indicates the degree of improvement in a patient's rheumatoid arthritis (RA), based on ACR guidelines. The ACR score= a percentage. To qualify for a score of 20, 50 or 70 (ACR20, ACR50 or ACR70), the patient must have &gt;=20%, &gt;=50% or &gt;=70%, respectively, fewer tender joints and &gt;=20%, &gt;=50% or &gt;=70%, respectively, fewer swollen joints and show 20%, 50% or 70%, respectively, improvement in at least 3 of the following: patient overall assessment of his/her RA, physician global assessment of the patient’s RA, patient self-assessment of pain, patient self-assessment of physical functioning, and results of an erythrocyte sedimentation rate or C-reactive protein test (to assess inflammation). Treatment groups represent treatment received in the short term period. Percentage calculated as n/m with n=number of paticipants with sustained ACR response at Day 533; m= long term participants who received at least one dose of drug and were ACR responders in the short term period.</description>
          <population>m=Long term period participants who received at least one dose of drug and were ACR responders in short term period: ACR20= 49, 46; ACR50= 35, 34; ACR70= 20, 16. n=number of paticipants with sustained ACR response at Day 533. n/m = percentage</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR 20 (n/m= 47/49; 45/46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.9" lower_limit="86.0" upper_limit="99.5"/>
                    <measurement group_id="O2" value="97.8" lower_limit="88.5" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 50 (n/m= 30/35; 32/34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7" lower_limit="69.7" upper_limit="95.2"/>
                    <measurement group_id="O2" value="94.1" lower_limit="80.3" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR 70 (n/m= 15/20; 15/16)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="50.9" upper_limit="91.3"/>
                    <measurement group_id="O2" value="93.8" lower_limit="69.8" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in HAQ-DI Score at Day 533 in Long Term Period</title>
        <description>Adjusted mean. The Health Assessment Questionnaire Disability Index (HAQ-DI) assesses patients' functional ability by rating their abilities over the previous week. At least 2 questions are asked from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. Treatment groups represent treatment received in the short term period. Baseline is Day 1 of the study or last non-missing pre-treatment value.</description>
        <time_frame>Baseline to Day 533</time_frame>
        <population>Number of participants with both baseline and post-baseline measurements in HAQ-DI. Treatment groups represent treatment received in the short term period.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in HAQ-DI Score at Day 533 in Long Term Period</title>
          <description>Adjusted mean. The Health Assessment Questionnaire Disability Index (HAQ-DI) assesses patients' functional ability by rating their abilities over the previous week. At least 2 questions are asked from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. Treatment groups represent treatment received in the short term period. Baseline is Day 1 of the study or last non-missing pre-treatment value.</description>
          <population>Number of participants with both baseline and post-baseline measurements in HAQ-DI. Treatment groups represent treatment received in the short term period.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" lower_limit="-0.87" upper_limit="-0.55"/>
                    <measurement group_id="O2" value="-0.71" lower_limit="-0.89" upper_limit="-0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Health Assessment Questionnaire (HAQ) Response at Day 533 in Long Term Period</title>
        <description>The Health Assessment Questionnaire (HAQ) disability index assesses patients' functional ability by rating their abilities over the previous week. At least 2 questions are asked from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The higher the number the worse the outcome. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. HAQ response=reduction of at least 0.30 units in HAQ score from baseline. The percentage of participants with a reduction of at least 0.30 units in their HAQ score from baseline is presented. Baseline is Day 1 of the study or last non-missing pre-treatment value. Treatment groups represent treatment received in the short term period.</description>
        <time_frame>Day 533</time_frame>
        <population>N=number of participants treated with at least 1 dose of study drug and with HAQ data available. n=number of participants with HAQ response. n/N = 41/52 and 31/51 in SC and IV arms, respectively. Treatment groups represent treatment received in the short term period.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Health Assessment Questionnaire (HAQ) Response at Day 533 in Long Term Period</title>
          <description>The Health Assessment Questionnaire (HAQ) disability index assesses patients' functional ability by rating their abilities over the previous week. At least 2 questions are asked from each of 8 categories: dressing and grooming, hygiene, arising, reach, eating, grip, walking, and common daily activities. Patients rate difficulty performing specific tasks: 0=without difficulty, 1=with some difficulty, 2=with much difficulty, and 3=unable to do. The higher the number the worse the outcome. The sum of the categories score (the highest scored item in the category) is divided by the number of categories answered, yielding a score from 0-3. HAQ response=reduction of at least 0.30 units in HAQ score from baseline. The percentage of participants with a reduction of at least 0.30 units in their HAQ score from baseline is presented. Baseline is Day 1 of the study or last non-missing pre-treatment value. Treatment groups represent treatment received in the short term period.</description>
          <population>N=number of participants treated with at least 1 dose of study drug and with HAQ data available. n=number of participants with HAQ response. n/N = 41/52 and 31/51 in SC and IV arms, respectively. Treatment groups represent treatment received in the short term period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.8" lower_limit="65.3" upper_limit="88.9"/>
                    <measurement group_id="O2" value="60.8" lower_limit="46.1" upper_limit="74.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in DAS28-CRP From Baseline at Day 533 in Long Term Period</title>
        <description>The Disease Activity Score 28 using C-Reactive Protein (DAS28-CRP) is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient’s global assessment of health (ranging from very good to very bad). An overall DAS &gt;5.1 implies active disease; &lt;3.2, well controlled disease; and &lt;2.6, remission.). Treatment groups represent treatment received in the short term period. Baseline is Day 1 of the study or last non-missing pre-treatment value.</description>
        <time_frame>Baseline to Day 533</time_frame>
        <population>Participants treated with at least 1 dose of study drug and who had both baseline and post-baseline measurements were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in DAS28-CRP From Baseline at Day 533 in Long Term Period</title>
          <description>The Disease Activity Score 28 using C-Reactive Protein (DAS28-CRP) is a measure of disease activity in rheumatoid arthritis (RA) and assesses the 28 joints RA commonly affects; the score includes the number of tender and swollen joints (out of 28), CRP level (a measure of inflammation in the blood), and the patient’s global assessment of health (ranging from very good to very bad). An overall DAS &gt;5.1 implies active disease; &lt;3.2, well controlled disease; and &lt;2.6, remission.). Treatment groups represent treatment received in the short term period. Baseline is Day 1 of the study or last non-missing pre-treatment value.</description>
          <population>Participants treated with at least 1 dose of study drug and who had both baseline and post-baseline measurements were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.27" lower_limit="-3.58" upper_limit="-2.97"/>
                    <measurement group_id="O2" value="-3.49" lower_limit="-3.82" upper_limit="-3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Long-term Period: Number of Participants With Electrolyte Laboratory Values Meeting the Criteria for Marked Abnormality</title>
        <description>LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Sodium (mEq/L): &lt;0.95*LLN or &gt;1.05*ULN, or if preRX&lt;LLN, use &lt;0.95*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.05*preRX or &lt;LLN; potassium (mEq/L): &lt;0.9*LLN or &gt;1.1*ULN, or if preRX&lt;LLN, use &lt;0.9*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.1*preRX or &lt;LLN; chloride (mEq/L): &lt;0.75*LLN or &gt;1.125*ULN, or if preRX&lt;LLN, use &lt;0.75*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.25*preRX or &lt;LLN; calcium (mg/dL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX&lt;LLN, use &lt;0.75*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.25*preRX or &lt;LLN; phosphorus (mg/dL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX&lt;LLN, use &lt;0.67*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.33*preRX or &lt;LLN.</description>
        <time_frame>Baseline to Day 533</time_frame>
        <population>All randomized participants who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous (SC) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
          <group group_id="O2">
            <title>Intravenous (IV) Abatacept, 125 mg</title>
            <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.
Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo).
Follow-up period was up to 168 days after the last dose of drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Long-term Period: Number of Participants With Electrolyte Laboratory Values Meeting the Criteria for Marked Abnormality</title>
          <description>LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Sodium (mEq/L): &lt;0.95*LLN or &gt;1.05*ULN, or if preRX&lt;LLN, use &lt;0.95*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.05*preRX or &lt;LLN; potassium (mEq/L): &lt;0.9*LLN or &gt;1.1*ULN, or if preRX&lt;LLN, use &lt;0.9*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.1*preRX or &lt;LLN; chloride (mEq/L): &lt;0.75*LLN or &gt;1.125*ULN, or if preRX&lt;LLN, use &lt;0.75*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.25*preRX or &lt;LLN; calcium (mg/dL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX&lt;LLN, use &lt;0.75*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.25*preRX or &lt;LLN; phosphorus (mg/dL): &lt;0.75*LLN or &gt;1.25*ULN, or if preRX&lt;LLN, use &lt;0.67*preRX or &gt;ULN, or if preRX&gt;ULN, use 1.33*preRX or &lt;LLN.</description>
          <population>All randomized participants who received at least 1 dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sodium, serum, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, serum, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, serum, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, serum, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, serum, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, serum, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, total, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, total, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus, inorganic, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus, inorganic, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 to 6 months post last dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Abatacept Long-term (LT) SC 125 mg</title>
          <description>Long-term period: All participants received weekly SC abatacept, 125 mg, for 1 year (52 weeks) without any IV infusions (active or placebo). Follow-up was up to 168 days after the last dose of drug.</description>
        </group>
        <group group_id="E2">
          <title>Short Term Intravenous (IV) Abatacept, 125 mg</title>
          <description>Short-term period: Participants received IV abatacept, 125 mg, infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. Participants also received subcutaneous (SC) injections of placebo.</description>
        </group>
        <group group_id="E3">
          <title>Short Term Subcutaneous (SC) Abatacept, 125 mg</title>
          <description>Short-term period: Participants received SC abatacept, 125 mg, injections weekly, after an intravenous (IV) abatacept loading dose on Day 1, based on body weight. Participants also received SC injections of placebo, with a loading dose of IV abatacept (and not IV placebo) administered on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Medical device complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Dacryocystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pneumonia cryptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Extranodal marginal zone B-cell lymphoma (MALT type)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

